In a Time of Universal Deceit, Telling the Truth is Revolutionary.
Monday, July 22, 2024

F.D.A. Revises Its Letter for Nonapproval of Drugs

Drug makers whose products are not ready for approval in the U.S. will soon get the word from regulators in a new format intended partly to avoid scaring investors.

Facebook
Twitter
LinkedIn

Drug makers whose products are not ready for approval in the U.S. will soon get the word from regulators in a new format intended partly to avoid scaring investors.